Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis To Pull Valturna From U.S. Market As FDA Warns Of Risks With Aliskiren Meds

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA warns that use of aliskiren-containing blood pressure drugs with ACE inhibitors or angiotensin receptor blockers may increase risk of kidney impairment, hypotension and hyperkalemia; Novartis to continue to sell four other aliskiren products.

You may also be interested in...



NME Exclusivity Petitions Expand; Ferring Request For Colon-Cleansing Combo Has Urgency

Ferring requests five years of marketing exclusivity for Prepopik; Gilead also has asked FDA to award five years of exclusivity for active ingredients in a combination product that has not been previously approved, but Gilead has patents to fall back on while Ferring has none.

EU And U.S. Regulators Toughen CV Monitoring Requirements For Novartis's Gilenya

A review of a potential association between Novartis's oral multiple sclerosis therapy Gilenya and sudden death was inconclusive, say EU regulators, but monitoring requirements are still strengthened as a precaution.

EU And U.S. Regulators Toughen CV Monitoring Requirements For Novartis's Gilenya

A review of a potential association between Novartis's oral multiple sclerosis therapy Gilenya and sudden death was inconclusive, say EU regulators, but monitoring requirements are still strengthened as a precaution.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel